Need for a trial of solanezumab in mild Alzheimer’s diseaseBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4441 (Published 01 September 2015) Cite this as: BMJ 2015;351:h4441
- David Torgerson, director1
- 1York Trials Unit, University of York, York, UK
McCartney is right to be cautious about the effectiveness of solanezumab in Alzheimer’s disease, which she says might be a chance finding.1 But this is not because of the relatively small size of the trial but the nature of testing subgroups within an overall …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial